Welcome to our dedicated page for Adc Therapeutics Sa news (Ticker: ADCT), a resource for investors and traders seeking the latest updates and insights on Adc Therapeutics Sa stock.
ADC Therapeutics SA reports news on its commercial-stage oncology business focused on antibody-drug conjugates. The company markets ZYNLONTA (loncastuximab tesirine-lpyl), a CD19-directed ADC with FDA accelerated approval and European Commission conditional approval for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy.
Recurring updates cover ZYNLONTA product revenue, manufacturing and commercialization activity, clinical development in combination regimens and earlier lines of therapy, including LOTIS program studies, and corporate financing matters. Company news also includes quarterly financial results, investor presentations, conference participation and equity inducement grants under its compensation plans.
ADC Therapeutics (NYSE: ADCT) announced a permanent J-code, J9359, for ZYNLONTA® effective April 1, 2022. This J-code simplifies the reimbursement process for physicians and improves patient access to treatment. ZYNLONTA, a CD19-directed antibody drug conjugate, is FDA-approved for relapsed or refractory large B-cell lymphoma. The company aims to expand its U.S. presence beyond academic institutions into more community accounts, increasing predictability in reimbursement through the J-code.
ADC Therapeutics, a biotechnology company focused on cancer treatment, announced the filing of its Annual Report on Form 20-F for the fiscal year ending December 31, 2021, with the SEC. The report, detailing comprehensive financial data and performance metrics, is accessible via the SEC website and the company's investor section. ADC's targeted antibody drug conjugates, like ZYNLONTA, which is FDA-approved for treating specific types of lymphoma, signify its commitment to innovative cancer therapies, alongside ongoing clinical developments for other ADCs.
ADC Therapeutics reported ZYNLONTA® net sales of $17.0 million for Q4 2021 and $33.9 million for FY 2021 following its May launch. The LOTIS-5 Phase 3 trial combining ZYNLONTA with rituximab has completed its safety lead-in and is now enrolling randomized participants. The company plans to discontinue the LOTIS-3 trial while focusing on the second-line opportunity for ZYNLONTA. R&D expenses dropped to $42.5 million for Q4, whereas net loss was $34.4 million for the quarter, improving from last year. The company aims to expand ZYNLONTA's availability and advance its clinical pipeline in 2022.
ADC Therapeutics (NYSE: ADCT), a biotechnology firm focused on cancer treatment, announced that CEO Chris Martin will participate in a fireside chat at Cowen’s 42nd Annual Health Care Conference on March 8 at 2:10 p.m. EST. A live webcast will be available on the company's Investors page.
The company develops next-generation antibody drug conjugates, including the FDA-approved ZYNLONTA® and others in clinical trials.
ADC Therapeutics (NYSE: ADCT) will host a conference call on March 3, 2022, at 8:30 a.m. ET to discuss its Q4 and year-end 2021 financial results and provide business updates. This call aims to inform investors about the company's performance and strategic direction. ADC Therapeutics specializes in targeted antibody drug conjugates for cancer treatment, with an FDA-approved product, ZYNLONTA®, for specific lymphoma treatments. The presentation will be available live and archived on their investor website.
ADC Therapeutics (NYSE: ADCT) has released its inaugural Environmental, Social, and Governance (ESG) report, showcasing its dedication to patient care and sustainable innovation. This report serves as a benchmark for future progress and reflects the company's commitment to ethical business practices. Key highlights include a review of global ESG efforts, a focus on patient safety and support, and a commitment to enhancing human capital.
The report is available for review on the company's website.
ADC Therapeutics (NYSE: ADCT) is hosting a live webcast today from 9:00 to 11:00 a.m. EST, showcasing its ADC platform and solid tumor pipeline. The company celebrates the launch of ZYNLONTA® for DLBCL in the US, achieved within five years of initiating clinical development. CEO Chris Martin highlights the exploration of ADC technology in solid tumors like ovarian, breast, and prostate cancers. The webcast will cover ADC assets, including three clinical-stage programs and new developments targeting PSMA for advanced prostate cancer.
ADC Therapeutics (NYSE: ADCT) will have its CEO, Chris Martin, participate in a fireside chat at the virtual Guggenheim Oncology Conference on February 9, 2022, at 9:30 a.m. EST. The event will be accessible via a live webcast on the company's Investor Relations page, with a replay available for 30 days. ADC Therapeutics specializes in targeted antibody drug conjugates (ADCs) for cancer treatment, with products like ZYNLONTA® approved for certain lymphomas and ongoing trials for other therapies, demonstrating a commitment to advancing cancer treatment.
ADC Therapeutics (NYSE: ADCT), a biotechnology company focused on improving cancer treatment, will host a live webcast on February 8 from 9:00 to 11:00 a.m. ET. The event will showcase its antibody drug conjugate (ADC) platform and pipeline for solid tumors. CEO Chris Martin, Senior VP Patrick van Berkel, and CMO Joseph Camardo will present insights into the company's ADC technology and ongoing clinical trials, including ZYNLONTA® and Cami. The webcast will be available for replay for 30 days on the company's website.
org value="NYSE:ADCT"ADC Therapeutics has entered an exclusive license agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of ZYNLONTA® in location value="LC/jp"Japan. The agreement includes a $30 million upfront payment, potential milestones up to $205 million, and royalties based on net sales. This partnership expands ADC Therapeutics' global footprint and addresses the unmet need for effective cancer therapies in Japan. ZYNLONTA, a CD19-targeted antibody drug conjugate, is already approved in the U.S. for specific lymphoma indications.